Novo Nordisk, Zealand Pharma jump after Eli Lilly weight-loss data

** Shares in Danish drugmakers Novo Nordisk NOVOb.CO and Zealand Pharma ZELA.CO rise around 10% and 7%, respectively, after peer Eli Lilly's LLY.N weight-loss pill data fell short of expectations

** Lilly's weaker pill data helps restore investor confidence in Novo's obesity lead, easing fears of an imminent threat to Wegovy's dominance and pricing power, Nordnet analyst Per Hansen has said

** Up to the previous session's close, Novo and Zealand shares had lost more than half their value since the start of the year

** Shares in Gerresheimer GXIG.DE, maker of injector pens for Wegovy and Zepbound, also rise 4.7%, as weaker oral pill data points to sustained demand for injectable obesity treatments

** If gains hold, Novo shares will see their biggest one-day rise in two years